Home World News Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously... World News Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 253 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa March 10, 2020 Blind Customer Surprised With Sweet Message In Braille For Her Birthday August 28, 2021 Rapid Genetic Test Could Help Guide Brain Cancer Surgery May 8, 2025 Medicare Advantage Plans: Read the Fine Print November 16, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Sugemalimab FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle... Aromatase inhibitors cut breast cancer recurrence in younger patients Building a Balanced Breakfast
